动物造模,艾滋病 z-bio 2021-06-08 317

　　Two studies published in the United States, Science and Cell, believe that experimental vaccines based on multiple vaccination strategies may inhibit HIV infection.

　　A practical idea of traditional vaccines is to use an inactivated version of the virus to stimulate the body to produce antibodies. However, vaccines developed using "natural" HIV proteins cannot stimulate an effective immune response, which allows HIV to evade detection by the immune system and quickly mutate into new virus strains. Because it has sex.

　　The above two studies believe that a successful AIDS vaccine needs to contain a series of related but slightly different immunogens. After multiple immunizations, the human body can produce a variety of neutralizing antibodies against HIV. This is different from the traditional "enhanced vaccine" approach, which exposes the vaccinated person to the same immunogen multiple times.

　　These two studies are related to an immunogen called "eOD-GT860mer". After testing by the Scripps Research Institute and other institutions, it has been proven to bind and activate B cells with anti-HIV effects. The two studies used two different mouse models, and the results showed the hope of developing an effective AIDS vaccine based on this immunogen.

　　Science also published the third AIDS study led by Cornell University. Testing of artificial molecular complexes showed that this immunogen stimulated rabbits and monkeys to produce antibodies and be infected with HIV strains.

　　The National Institutes of Health funded these three studies, and in a statement, the three papers provided an "important new starting point" for the development of AIDS vaccines.